SU1537259A1 - Agent for developing dislike to tobacco and tobacco fumes - Google Patents

Abstract

The invention relates to medicine, in particular to drugs for the treatment of tobacco smoking and nicotine withdrawal. It is proposed to use the well-known drug mebicar / 2, 4, 6, 8-tetramethyl-2, 4, 6, 8-tetraazabicyclo / 3, 3, 0-octanedione-3, 7 / for a new purpose as a means of suppressing craving for nicotine. and tobacco smoke. New useful property mebikar confirmed in experimental and clinical studies. The use of the drug leads to the relief of nicotine withdrawal, reduces the subjective haunting, is accompanied by an increase in the "saturability" of smoking. Assign courses of 3 to 5 weeks depending on the severity of nicotinism in a daily dose of 1.8 - 2.4 g.

Description

The invention relates to medicine, in particular to drugs for the treatment of nicotine abstinence.

The purpose of the invention is to suppress the craving for nicotine.

The use of 2,4,6,8-tetramethyl-2,4,6,8-tstrazabicyclo (3,3,0) octan-dione-3,7 is proposed as a treatment for nicotine withdrawal and attraction to tobacco smoking.

CH3 Cr

5, 3

II

SN s

The use of the well-known drug mebicar for a new purpose to relieve tobacco smoking was theoretically justified by the presence of neurosis-like conditions, often provoking smoking, as well as the absence of side effects (mental depression, neuroplegia, addiction and addiction) that accompany the use of other tranquilizers. The low effectiveness of N-cholinomimetics (nicotine, anabasin) used to relieve smoking cessation, as well as the substitution nature of their action, has motivated the search for means to suppress the craving for nicotine and tobacco smoke, among other classes of compounds.

It was established in the experiment (the inhibitory effect of mebicar on the voluntary consumption of nicotine solution

CO 1 b sp

WITH

tina and inhalation of tobacco smoke in rats. Mebicar demonstrated advantages over tranquilizers (diazepam, amisyl) and H-cho with phshomimetics (nicotine, anabazine and acanoyl).

Experimental data allowed mebicar to be recommended for the treatment of patients wishing to stop smoking.

The use leads to the relief of nicotine withdrawal, reduces the subjective craving to smoking, is accompanied by an increase in 15 saturation from smoking.

The drug is prescribed for 3–5 weeks, depending on the severity of niotinism in a daily dose of 1.8-2.4 g. The Pharmacological Committee of the Ministry of Health of the USSR Mebicar approved the use of E medical practice for additional reasons for the treatment of tobacco smoking.

Example 1. Patient S., 23 years old. 25 Smokes for 6 years from 10 to 20 hours per day. Fearing a violation of the state or health, wants to quit smoking, rta does not hope his own volitional efforts. Emotive emotionally 30 labile, restless sleep. The patient was prescribed medication therapy: mebicar 1.8 g per day in 3 doses E: for 3 weeks. Against the background of treatment II, during the first week, the patient progresses 35 кур, but notes a sharp decrease in the number of consumed igaret: from a few puffs to 2-3 cigarettes per day. At the same time, there is a decrease in the feeling of stress — 40 Sti, incontinence, and the reduction in smoking is reduced. From the 2nd week of treatment, the patient stopped smoking, complaints

It does not produce a state of health, sleep and appetite are satisfactory.

Discharged in good condition. After 3 months after a course of treatment with mebicar, smoking did not resume.

Example 2. Patient 0., 38 years old Received complaints of shortness of breath with little exertion (climbing stairs), paroxysmal cough, poor sleep, appetite, which causes smoking. Smokes since the age of 14, nowadays - 2 packs of cigarettes a day, 3-4 of them at night. I tried several times to stop smoking, including twice using chewing gum (gambazin). Attempts failed because they did not withstand the discomfort of the smoking cessation period. Diagnosis at admission: nicotinism II Art. Chronic bronchitis smoker. The patient was prescribed a course of treatment with mebicar 2.4 g per day for 4 divided doses for 5 weeks under conditions of smoking cessation.

After 4 days from the start of treatment, there is a decrease in the feeling of internal tension, a subjective reduction in the ha of smoking, improved sleep, increased appetite - there is a relief in nicotine withdrawal. By the end of the course of treatment, a decrease in cough, a decrease in the amount of sputum is noted.

Claims (1)

Discharged in good health, tons of ha to smoking is weakened. After 2 months after treatment, patient 0. completely refused from Kuoyeni. Invention Formula The use of mebicar as a means of suppressing attraction to nicotine and tobacco smoke. Editor G. Gerber Compiled by S. Bal kin Tehred L. Oliynyk Order 124 Circulation 528 VNIIPI State Committee for Inventions and Discoveries at the State Committee on Science and Technology of the USSR 113035, Moscow, Zh-35, Raushsk nab. 4/5 Proofreader S. Shekmar Subscription